Dogwood Therapeutics, Inc. Research and Development Expense
Dogwood Therapeutics, Inc. (DWTX) reported Research and Development Expense of $3.25 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- Dogwood Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $3.25M, a 26.33% increase year-over-year.
- Dogwood Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $2.67M, a 9.55% increase year-over-year.
- Dogwood Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $2.34M, a 0.94% increase year-over-year.
- Dogwood Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $14.52M, a 2613.45% increase year-over-year.
- Dogwood Therapeutics, Inc. research and development expense for fiscal 2025 was $21.87M, a 519.28% increase from fiscal 2024.
- Dogwood Therapeutics, Inc. research and development expense for fiscal 2024 was $3.53M, a 104.33% increase from fiscal 2023.
- Dogwood Therapeutics, Inc. research and development expense for fiscal 2023 was $1.73M, a 78.59% decline from fiscal 2022.
- Dogwood Therapeutics, Inc. research and development expense for fiscal 2022 was $8.07M, a 25.25% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.25M 10-Q · filed 2026-08-14 | $5.92M 10-Q · filed 2026-08-14 | $8.25M derived: sum of 3 quarters · filed 2026-08-14 | $22.78M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $2.67M 10-Q · filed 2026-05-15 | $5.01M derived: sum of 2 quarters · filed 2026-05-15 | $19.53M derived: sum of 3 quarters · filed 2026-05-15 | $22.10M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $2.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $16.86M derived: sum of 2 quarters · filed 2026-03-18 | $19.43M derived: sum of 3 quarters · filed 2026-08-14 | $21.87M 10-K · filed 2026-03-18 |
| 2025-09-30 | $14.52M 10-Q · filed 2025-11-07 | $17.09M derived: sum of 2 quarters · filed 2026-08-14 | $19.53M 10-Q · filed 2025-11-07 | $21.84M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $2.57M 10-Q · filed 2026-08-14 | $5.01M 10-Q · filed 2026-08-14 | $7.32M derived: sum of 3 quarters · filed 2026-08-14 | $7.86M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $2.44M 10-Q · filed 2026-05-15 | $4.75M derived: sum of 2 quarters · filed 2026-05-15 | $5.29M derived: sum of 3 quarters · filed 2026-05-15 | $5.62M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $2.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $2.85M derived: sum of 2 quarters · filed 2026-03-18 | $3.19M derived: sum of 3 quarters · filed 2026-03-18 | $3.53M 10-K · filed 2026-03-18 |
| 2024-09-30 | $535.16K 10-Q · filed 2025-11-07 | $871.25K derived: sum of 2 quarters · filed 2025-11-07 | $1.21M 10-Q · filed 2025-11-07 | $1.51M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $336.08K 10-Q · filed 2025-08-13 | $679.80K 10-Q · filed 2025-08-13 | $978.12K derived: sum of 3 quarters · filed 2025-08-13 | $1.35M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $343.72K 10-Q · filed 2025-05-09 | $642.04K derived: sum of 2 quarters · filed 2025-05-09 | $1.02M derived: sum of 3 quarters · filed 2025-05-09 | $1.57M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $298.32K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $672.52K derived: sum of 2 quarters · filed 2025-03-31 | $1.23M derived: sum of 3 quarters · filed 2025-03-31 | $1.73M 10-K · filed 2025-03-31 |
| 2023-09-30 | $374.20K 10-Q · filed 2024-11-08 | $932.04K derived: sum of 2 quarters · filed 2024-11-08 | $1.43M 10-Q · filed 2024-11-08 | $2.70M derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $557.84K 10-Q · filed 2024-08-09 | $1.06M 10-Q · filed 2024-08-09 | $2.33M derived: sum of 3 quarters · filed 2024-08-09 | $3.95M derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | $497.71K 10-Q · filed 2024-05-10 | $1.77M derived: sum of 2 quarters · filed 2024-05-10 | $3.39M derived: sum of 3 quarters · filed 2024-05-10 | $5.80M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | $1.27M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-08 | $2.89M derived: sum of 2 quarters · filed 2024-03-08 | $5.30M derived: sum of 3 quarters · filed 2024-03-08 | $8.07M 10-K/A · filed 2024-03-08 |
| 2022-09-30 | $1.62M 10-Q · filed 2023-11-13 | $4.03M derived: sum of 2 quarters · filed 2023-11-13 | $6.80M 10-Q · filed 2023-11-13 | $9.72M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $2.41M 10-Q · filed 2023-08-11 | $5.18M 10-Q · filed 2023-08-11 | $8.09M derived: sum of 3 quarters · filed 2023-08-11 | $11.06M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $2.77M 10-Q · filed 2023-05-12 | $5.69M derived: sum of 2 quarters · filed 2023-05-12 | $8.65M derived: sum of 3 quarters · filed 2023-05-12 | $11.86M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $2.92M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $5.88M derived: sum of 2 quarters · filed 2023-03-14 | $9.09M derived: sum of 3 quarters · filed 2023-03-14 | $10.80M 10-K · filed 2023-03-14 |
| 2021-09-30 | $2.96M 10-Q · filed 2022-11-14 | $6.17M derived: sum of 2 quarters · filed 2022-11-14 | $7.88M 10-Q · filed 2022-11-14 | $7.91M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $3.21M 10-Q · filed 2022-08-12 | $4.92M 10-Q · filed 2022-08-12 | $4.95M derived: sum of 3 quarters · filed 2022-08-12 | $5.06M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $1.71M 10-Q · filed 2022-05-13 | $1.74M derived: sum of 2 quarters · filed 2022-05-13 | $1.85M derived: sum of 3 quarters · filed 2022-05-13 | $1.87M derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | $32.07K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $140.16K derived: sum of 2 quarters · filed 2022-03-18 | $163.47K derived: sum of 3 quarters · filed 2022-03-18 | $194.01K 10-K · filed 2022-03-18 |
| 2020-09-30 | $108.09K 10-Q · filed 2021-11-12 | $131.41K derived: sum of 2 quarters · filed 2021-11-12 | $161.94K 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $23.32K 10-Q · filed 2021-08-13 | $53.86K 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $30.54K 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |